Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17422848 | 0.76 | MAPK1 (0.52) | MAPK1ALOX15ALDH1A1MAPTHTT | |
| SCHEMBL29804080 | 0.76 | EGFR (0.56) | MAPK1ALOX15EGFRALDH1A1MAPT | |
| SCHEMBL110445 | 0.76 | EGFR (0.56) | MAPK1ALOX15EGFRALDH1A1MAPT | |
| SCHEMBL29094004 | 0.76 | ADORA2A (0.36) | CNR1ALDH1A1MAPTHTTCNR2 | |
| SCHEMBL17678308 | 0.73 | EGFR (0.58) | MAPK1ALOX15EGFRTSHRLMNA | |
| SCHEMBL18731523 | 0.73 | ALOX15 (0.51) | MAPK1ALOX15CNR1ALDH1A1MAPT | |
| SCHEMBL4040939 | 0.72 | HTR7 (0.50) | MAPK1ALOX15CNR1ALDH1A1MAPT | |
| SCHEMBL17673722 | 0.71 | EGFR (0.56) | MAPK1ALOX15EGFRALDH1A1MAPT | |
| SCHEMBL15837038 | 0.71 | ALOX15 (0.54) | MAPK1ALOX15ALDH1A1MAPTHTT | |
| SCHEMBL24002834 | 0.71 | ALOX15 (0.55) | MAPK1ALOX15ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049503-B1 | QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES AS P38 KINASE INHIBITORS | AMGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7935709-B2 | 2-quinazolinone compounds and methods of use | AMGEN INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2049503-A1 | QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES AS P38 KINASE INHIBITORS | Amgen Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080032973-A1 | 2-Quinazolinone compounds and methods of use | AMGEN INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2008011032-A1 | QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES AS P38 KINASE INHIBITORS | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032973-A1 | 2-Quinazolinone compounds and methods of use | MAP3K1, MAP3K2, MAP3K7 | MAPK1 62/4885ALOX15 1437/4885EGFR 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.